Enliven Therapeutics, Inc. (ELVN): who owns it and who trades it
As of Nov 16, 2026, ELVN insiders reported 74 open-market sales worth $76.7M and no purchases in the last 12 months, with 31% of the sale value made under pre-set 10b5-1 plans. The largest seller was Orbimed Advisors Llc (10% owner), with $51.7M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Enliven Therapeutics
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ELVN
211 funds and institutions reported ELVN shares worth $4.1B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 16.5%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 10.03M | 16.46% | $509M | +47% |
| Orbimed Advisors LLC | 6.78M | 11.13% | $344M | -15% |
| Polar Capital Holdings Plc | 6.43M | 10.56% | $326M | +27% |
| BlackRock, Inc. | 4.36M | 7.16% | $221M | +18% |
| Vestal Point Capital, LP | 4.00M | 6.57% | $203M | +23% |
| Commodore Capital LP | 3.27M | 5.38% | $166M | No change |
| T. Rowe Price Associates | 2.90M | 4.77% | $147M | +2871% |
| California State Teachers Retirement System | 2.71M | 4.44% | $53.3M | +8378% |
| Vanguard Capital Management LLC | 2.57M | 4.22% | $130M | +18% |
| Citadel Advisors LLC | 2.07M | 3.40% | $105M | +19% |
| Fairmount Funds Management LLC | 1.86M | 3.05% | $94.2M | No change |
| Siren, L.L.C. | 1.77M | 2.91% | $90.1M | +138% |
| Bellevue Group AG | 1.49M | 2.45% | $75.6M | -36% |
| Geode Capital Management, LLC | 1.41M | 2.31% | $71.4M | +32% |
| First Light Asset Management, LLC | 1.36M | 2.23% | $69.1M | +574% |
| State Street Corp | 1.21M | 1.99% | $61.6M | +11% |
| Pictet Asset Management Holding SA | 1.16M | 1.91% | $59M | +25% |
| Adage Capital Partners Gp, L.l.c. | 1.08M | 1.78% | $55M | – |
| Novo Holdings A/s | 1.00M | 1.64% | $50.8M | -22% |
| First Turn Management, LLC | 954,360 | 1.57% | $48.4M | +53% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ELVN insiders reported $0 of open-market purchases and $76.7M of sales. 31% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 19, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 5,000 | $38.47 | $192K | Form 4 |
| Oct 19, 2026 | Benjamin Hohl | CFO | Sale plan | 6,018 | $38.48 | $232K | Form 4 |
| Oct 1, 2026 | J. Scott Garland | Director | Sale | 13,000 | $46.67 | $607K | Form 4 |
| Sep 17, 2026 | Benjamin Hohl | CFO | Sale plan | 3,535 | $50.03 | $177K | Form 4 |
| Sep 17, 2026 | Benjamin Hohl | CFO | Sale plan | 2,194 | $50.72 | $111K | Form 4 |
| Sep 17, 2026 | Benjamin Hohl | CFO | Sale plan | 289 | $51.49 | $14.9K | Form 4 |
| Sep 17, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 1,844 | $50.71 | $93.5K | Form 4 |
| Sep 17, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 2,916 | $50.03 | $146K | Form 4 |
| Sep 17, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 240 | $51.48 | $12.4K | Form 4 |
| Aug 17, 2026 | Benjamin Hohl | CFO | Sale plan | 4,630 | $58.35 | $270K | Form 4 |
| Aug 17, 2026 | Benjamin Hohl | CFO | Sale plan | 1,388 | $59.35 | $82.4K | Form 4 |
| Aug 17, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 3,900 | $58.37 | $228K | Form 4 |
| Aug 17, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 1,100 | $59.35 | $65.3K | Form 4 |
| Aug 4, 2026 | Mika K Derynck | Director | Sale plan | 158,795 | $60.21 | $9.6M | Form 4 |
| Jul 17, 2026 | Benjamin Hohl | CFO | Sale plan | 123 | $53.87 | $6.6K | Form 4 |
| Jul 17, 2026 | Benjamin Hohl | CFO | Sale plan | 2,638 | $53.38 | $141K | Form 4 |
| Jul 17, 2026 | Benjamin Hohl | CFO | Sale plan | 324 | $49.97 | $16.2K | Form 4 |
| Jul 17, 2026 | Benjamin Hohl | CFO | Sale plan | 369 | $51.48 | $19K | Form 4 |
| Jul 17, 2026 | Benjamin Hohl | CFO | Sale plan | 2,564 | $52.32 | $134K | Form 4 |
| Jul 17, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 2,063 | $52.39 | $108K | Form 4 |
| Jul 17, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 2,184 | $53.42 | $117K | Form 4 |
| Jul 17, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 63 | $53.92 | $3.4K | Form 4 |
| Jul 17, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 231 | $50.05 | $11.6K | Form 4 |
| Jul 17, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 459 | $51.55 | $23.7K | Form 4 |
| Jul 6, 2026 | Lori Anne Kunkel | Director | Sale plan | 5,889 | $50.84 | $299K | Form 4 |
| Jul 6, 2026 | Lori Anne Kunkel | Director | Sale plan | 4,111 | $49.98 | $205K | Form 4 |
| Jun 22, 2026 | Orbimed Advisors Llc +2 | 10% owner | Sale | 24,846 | $45.38 | $1.1M | Form 4 |
| Jun 22, 2026 | Orbimed Advisors Llc +2 | 10% owner | Sale | 46,776 | $45.00 | $2.1M | Form 4 |
| Jun 22, 2026 | Orbimed Advisors Llc +2 | 10% owner | Sale | 787,024 | $45.38 | $35.7M | Form 4 |
| Jun 22, 2026 | Orbimed Advisors Llc +2 | 10% owner | Sale | 1,477 | $45.00 | $66.5K | Form 4 |
| Jun 17, 2026 | Benjamin Hohl | CFO | Sale plan | 1,238 | $44.75 | $55.4K | Form 4 |
| Jun 17, 2026 | Benjamin Hohl | CFO | Sale plan | 3,401 | $43.86 | $149K | Form 4 |
| Jun 17, 2026 | Benjamin Hohl | CFO | Sale plan | 1,379 | $42.79 | $59K | Form 4 |
| Jun 17, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 1,268 | $42.83 | $54.3K | Form 4 |
| Jun 17, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 2,599 | $43.87 | $114K | Form 4 |
| Jun 17, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 1,133 | $44.74 | $50.7K | Form 4 |
| Jun 15, 2026 | Orbimed Advisors Llc +2 | 10% owner | Sale | 9,086 | $45.02 | $409K | Form 4 |
| Jun 15, 2026 | Orbimed Advisors Llc +2 | 10% owner | Sale | 272,322 | $45.02 | $12.3M | Form 4 |
| Jun 5, 2026 | Lori Anne Kunkel | Director | Sale plan | 354 | $35.82 | $12.7K | Form 4 |
| Jun 5, 2026 | Lori Anne Kunkel | Director | Sale plan | 7,779 | $34.28 | $267K | Form 4 |
| Jun 5, 2026 | Lori Anne Kunkel | Director | Sale plan | 1,867 | $35.36 | $66K | Form 4 |
| May 18, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 1,302 | $40.25 | $52.4K | Form 4 |
| May 18, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 3,475 | $39.53 | $137K | Form 4 |
| May 18, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 223 | $41.21 | $9.2K | Form 4 |
| Apr 17, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 2,441 | $48.06 | $117K | Form 4 |
| Apr 17, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 140 | $45.81 | $6.4K | Form 4 |
| Apr 17, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 2,419 | $47.39 | $115K | Form 4 |
| Mar 25, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 40,000 | $35.10 | $1.4M | Form 4 |
| Mar 17, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 5,000 | $27.76 | $139K | Form 4 |
| Mar 10, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 10,129 | $30.19 | $306K | Form 4 |
| Mar 9, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 29,871 | $30.02 | $897K | Form 4 |
| Mar 6, 2026 | Benjamin Hohl | CFO | Sale | 10,000 | $29.58 | $296K | Form 4 |
| Feb 17, 2026 | Richard A. Heyman | Director | Sale plan | 1,230 | $26.18 | $32.2K | Form 4 |
| Feb 17, 2026 | Helen Louise Collins | CHIEF MEDICAL OFFICER | Sale plan | 45,000 | $26.17 | $1.2M | Form 4 |
| Feb 6, 2026 | Joseph P Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale plan | 5,000 | $29.04 | $145K | Form 4 |
| Jan 20, 2026 | Joseph P Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale plan | 14,509 | $26.90 | $390K | Form 4 |
| Jan 20, 2026 | Joseph P Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale plan | 5,491 | $26.37 | $145K | Form 4 |
| Jan 20, 2026 | Richard A. Heyman | Director | Sale plan | 512 | $26.46 | $13.5K | Form 4 |
| Jan 20, 2026 | Richard A. Heyman | Director | Sale plan | 718 | $26.96 | $19.4K | Form 4 |
| Jan 9, 2026 | Anish Patel | CHIEF OPERATING OFFICER | Sale plan | 243 | $28.50 | $6.9K | Form 4 |
| Jan 9, 2026 | Anish Patel | CHIEF OPERATING OFFICER | Sale plan | 48,057 | $27.98 | $1.3M | Form 4 |
| Jan 9, 2026 | Joseph P Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale plan | 41,198 | $24.90 | $1M | Form 4 |
| Jan 9, 2026 | Joseph P Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale plan | 50,000 | $29.13 | $1.5M | Form 4 |
| Jan 9, 2026 | Richard A. Heyman | Director | Sale plan | 4,285 | $25.00 | $107K | Form 4 |
| Jan 8, 2026 | Joseph P Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale plan | 7,500 | $20.13 | $151K | Form 4 |
| Jan 8, 2026 | Joseph P Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale plan | 33,802 | $24.92 | $842K | Form 4 |
| Jan 8, 2026 | Richard A. Heyman | Director | Sale plan | 8,015 | $25.04 | $201K | Form 4 |
| Jan 8, 2026 | Richard A. Heyman | Director | Sale plan | 1,620 | $25.00 | $40.5K | Form 4 |
| Dec 19, 2025 | Joseph P Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale plan | 5,000 | $16.84 | $84.2K | Form 4 |
| Dec 8, 2025 | Anish Patel | CHIEF OPERATING OFFICER | Sale plan | 4,958 | $20.76 | $103K | Form 4 |
| Dec 8, 2025 | Anish Patel | CHIEF OPERATING OFFICER | Sale plan | 1,705 | $21.78 | $37.1K | Form 4 |
| Nov 19, 2025 | Joseph P Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale plan | 12,008 | $22.30 | $268K | Form 4 |
| Nov 19, 2025 | Joseph P Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale plan | 492 | $23.09 | $11.4K | Form 4 |
| Nov 17, 2025 | Samuel Kintz | CEO | Sale plan | 12,500 | $21.82 | $273K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Orbimed Advisors Llc | 10% owner | – | $51.7M | Jun 22, 2026 |
| Mika K Derynck | Director | – | $9.6M | Aug 4, 2026 |
| Helen Louise Collins | CHIEF MEDICAL OFFICER | – | $5.6M | Oct 19, 2026 |
| Joseph P Lyssikatos | CHIEF SCIENTIFIC OFFICER | – | $4.5M | Feb 6, 2026 |
| Benjamin Hohl | CHIEF FINANCIAL OFFICER | – | $1.8M | Oct 19, 2026 |
| Anish Patel | CHIEF OPERATING OFFICER | – | $1.5M | Jan 9, 2026 |
| Lori Anne Kunkel | Director | – | $850K | Jul 6, 2026 |
| J. Scott Garland | Director | – | $607K | Oct 1, 2026 |
| Richard A. Heyman | Director | – | $413K | Feb 17, 2026 |
| Samuel Kintz | PRESIDENT AND CEO, Director | – | $273K | Nov 17, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ELVN short interest
High short interest. 14.0% of ELVN shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 101%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 10.29M ELVN shares were sold short, 14.0% of the shares outstanding, up 10.3% from the report before. At the average daily volume of 1.81M shares, buying them all back would take about 5.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 10.29M | 13.99% | +10% | 1.81M | 5.7 |
| Oct 15, 2026 | 9.33M | 12.74% | -10% | 1.25M | 7.5 |
| Sep 30, 2026 | 10.36M | 14.13% | +20% | 1.89M | 5.5 |
| Sep 15, 2026 | 8.62M | 11.77% | +0% | 956,494 | 9.0 |
| Aug 31, 2026 | 8.60M | 11.74% | +4% | 776,607 | 11.1 |
| Aug 14, 2026 | 8.26M | 11.27% | +1% | 1.30M | 6.3 |
| Jul 31, 2026 | 8.15M | 11.13% | -6% | 712,367 | 11.4 |
| Jul 15, 2026 | 8.65M | 14.21% | +1% | 919,272 | 9.4 |
| Jun 30, 2026 | 8.53M | 14.00% | +57% | 2.76M | 3.1 |
| Jun 15, 2026 | 5.43M | 8.91% | +4% | 2.08M | 2.6 |
| May 29, 2026 | 5.21M | 8.56% | +2% | 597,268 | 8.7 |
| May 15, 2026 | 5.12M | 8.41% | -3% | 636,686 | 8.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Enliven Therapeutics company events
Enliven Therapeutics filed 10 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Oct 14, 2026LeadershipThe board of directors of Enliven Therapeutics, Inc. increased the size of the Board from seven to eight directors and appointed Kristine Ball to serve as a Class II director, with a term expiring at the Company’s 2028 annual meeting of stockholders, and as a member of the Audit Committee of the… Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jun 12, 2026AgreementEnliven Therapeutics, Inc. entered into an underwriting agreement with Jefferies LLC, Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Barclays Capital Inc. as representatives of the several underwriters named therein, relating to the issuance and sale in a public offering of 8,933,334 shares… Filing
- Jun 11, 2026AnnouncementThe Company announced updated positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with CML and key outcomes from the Company’s End-of-Phase 1 meeting with the U.S. Food and Drug Administration. Filing
- Jun 10, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 3, 2026ResultsReleased financial results. Filing
- Jan 7, 2026LeadershipThe board of directors of Enliven Therapeutics, Inc. appointed Scott Garland to serve as a Class I director, with a term expiring at the Company’s 2027 annual meeting of stockholders, and as the Chair of the Nominating and Corporate Governance Committee of the Board, effective January 7, 2026. Filing
- Dec 11, 2025LeadershipEnliven Therapeutics, Inc. announced the appointment of Richard Fair as the Company’s President and Chief Executive Officer and as a member of the board of directors of the Company, effective as of December 11, 2025. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Enliven Therapeutics financials
Famous investors that hold ELVN
4 of the 50 well-known investors we track reported holding ELVN in their latest 13F filing. The largest position is Ken Griffin's, worth $57M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.24M | $57M | 0.0% | -40% |
| Israel Englander · Millennium Management | Q3 2026 | 493,615 | $22.6M | 0.0% | +20% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 170,735 | $7.8M | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 13,601 | $623K | 0.0% | -66% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ELVN in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Vestal Point Capital, LP | 13G/A | 4.4% |
| Nov 16, 2026 | Vestal Point Capital, LP | 13G/A | 4.4% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 7.1% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 7.1% |
Questions about Enliven Therapeutics, Inc. (ELVN) stock
Who owns the most ELVN stock?
The largest reported owner of Enliven Therapeutics, Inc. (ELVN) is FMR LLC (Fidelity), with 16.5% of the company. In total, 211 funds and institutions reported holding ELVN at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are ELVN insiders buying or selling?
In the last 12 months, ELVN insiders reported no open-market purchases and 74 sales worth $76.7M. The latest trade was on Oct 19, 2026. See every trade.
What is the short interest in ELVN?
As of Oct 30, 2026, 10.29M ELVN shares were sold short, 14.0% of the shares outstanding, up 10.3% from the report before. At the average daily volume of 1.81M shares, buying them all back would take about 5.7 trading days (days to cover). See the history.
Which famous investors hold ELVN?
4 of the 50 well-known investors we track reported ELVN in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $57M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.